Pyrazolopyrimidine compounds for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-9562047-B2
Application number	US-201314436356-A
Country	US
Kind code	B2
Filing date	Oct 16, 2013
Priority date	Oct 17, 2012
Publication date	Feb 7, 2017
Grant date	Feb 7, 2017

Abstract

Compounds of Formula I are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof.

First claim

That which is claimed is:

1. A compound selected from the following:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.

8. A method of treating cancer in a subject in need thereof, comprising administering to said subject a compound of claim 1 in an amount effective to treat said cancer, wherein said cancer is selected from the group consisting of myeloid leukemia, lymphoblastic leukemia, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine, and brain cancer.

9. A method of inhibiting blood clot formation in a subject in need thereof, comprising administering to said subject the compound of claim 1 in an amount effective to inhibit blood clot formation.

Assignees

• Univ North Carolina Chapel Hill

Inventors

• Wang Xiaodong
• Liu Jing
• Yang Chao
• Zhang Weihe
• Frye Stephen
• Kireev Dmitri

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title